An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials

BACKGROUND: Treatment with nusinersen has demonstrated significant and clinically meaningful benefits in clinical trials in infants and children with spinal muscular atrophy (SMA). OBJECTIVE: The objective of this analysis was to characterize the safety of nusinersen across the clinical trial progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Darras, Basil T., Farrar, Michelle A., Mercuri, Eugenio, Finkel, Richard S., Foster, Richard, Hughes, Steven G., Bhan, Ishir, Farwell, Wildon, Gheuens, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776494/
https://www.ncbi.nlm.nih.gov/pubmed/31420846
http://dx.doi.org/10.1007/s40263-019-00656-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776494/
https://www.ncbi.nlm.nih.gov/pubmed/31420846
http://dx.doi.org/10.1007/s40263-019-00656-w

Ejemplares similares